VaxGen Gets a Boost From Anthrax Contract
Biotech VaxGen (VXGN) is adding to its huge September run-up as shares rise on word it was awarded an $80 million government contract for an anthrax vaccine.
In recent trading, shares were up 87 cents, or 7.2%, to $12.94.
The company said the three-year National Institute of Allergy and Infectious Diseases contract will pay for up to 3 million doses of the vaccine, which will be tested on animals.
Shares of VaxGen have nearly tripled over the past month, rising from a close of $4.32 on Sept. 2. While its AIDS vaccine results bombed earlier this year, investors have become excited over the company's promise in developing reliable anthrax and smallpox vaccines.Those vaccines have a good shot at attracting a chunk of the $6 billion the government will spend in the next 10 years on the so-called Project BioShield, a program to protect Americans from bioterrorism.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV